Membranoproliferative glomerulonephritis: a new classification and pathogenesis


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Currently membranoproliferative glomerulonephritis (MPGN) is believed to be a morphological variant of glomerular injury arising in a variety of disease entities. Earlier MPGN was divided into primary, idiopathic and secondary MPGN. The primary MPGN included MPGN і, II and III depending on the localization of deposits. Given recent advances in understanding the etiology and pathogenesis of the disease, this classification has been changed. Studying the composition of deposits with immunofluorescence microscopy allowed to identify a special group of nephritis associated with dysregulation of the alternative pathway of complement. This group became known as СЗ glomerulopathy. The main representatives of this group are dense deposit disease previously known as type II MPGN and СЗ glomerulonephritis. The review presents the new data on the pathogenesis and classification of MPGN.

Толық мәтін

Рұқсат жабық

Авторлар туралы

V. Yurova

Email: val84-05@mail.ru

N. Kozlovskaya

Әдебиет тізімі

  1. Sethi S., Fervenza F.C. Membranoproliferative glomerulonephritis - a new look at an old entity. N. Engl. J. Med. 2012;366:1119-1131.
  2. Bomback A.S., Appel G.B. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat. Rev. Nephrol. 2012;8:634-642.
  3. Cook H.T., Pickering M.C. Histopathology of MPGN and C3 glomerulopathies. Nat. Rev. Nephrol. 2015;11:14-22.
  4. Смирнов А.В., Добронравов В.А., Сиповский В.Г., Трофименко И.И., Пирожков И.А., Каюков И.Г., Лебедев К.И. Клинические рекомендации по диагностике, лечению и прогнозу мембранопролиферативного гломерулонефрита. Нефрология. 2014;18(6):82-94.
  5. D’Agati V.D., Bomback A.S. C3 glomerulopathy: What’s in a name? Kidney Int. 2012;82:379-381.
  6. Habib R., Gubler M., Loirat C., Mäiz H.B., Levy M. Dense deposit disease: A variant of membranoproliferative glomerulonephritis. Kidney Int. 1975; 7:204-215.
  7. Burkholder P.M., Marchand A., Krueger R.P. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab. Invest. 1970;23:459-479.
  8. Strife C.F., McEnery P.T., McAdams A.J., West C.D. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin. Nephrol. 1977;7:65-72.
  9. Anders D., Agricola B., Sippel M., Thoenes W. Basement membrane changes in membranoproliferative glomerulonephritis. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch. A Pathol. Anat. Histol. 1977;376:1-19.
  10. Sethi S., Fervenza F.C. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 2011;31:341-348.
  11. Sethi S., Nester C.M., Smith R.J. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012;81:434-441.
  12. Rennke H.G. Secondary membranoproliferative glomerulonephritis. Kidney Int. 1995;47:643-656.
  13. Rocatello D., Fornasierri A., Gianchino O., Rossi D., Beltrame A., Banfi G., Confalonieri R., Tarantino A., Pasquali S., Amoroso A., Savoldi S., Colombo V., Manno C., Ponzetto A., Moriconi L., Pani A., Rustichelli R., Di Belgiojoso G.B., Comotti C., Quarenghi M.I. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am. J. Kidney Dis. 2007;49:69-82.
  14. Добронравов В.А., Дунаева Н.В. Поражение почек и хронический вирусный гепатит С. Нефрология. 2008;12(4):9-19.
  15. Morales J.M., Kamar N., Rostaing L. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. In: Morales J.M., eds. Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Contrib. Nephrol. Basel, Karger, 2012. P. 10-23.
  16. Семененко Н.А. Клинико-лабораторная диагностика воспаления при инфекционном эндокардите. Сеченовский вестник. 2013;3(13):54-60.
  17. Sethi S., Zand L., Leung N., Smith R.J., Jevremonic D., Herrmann S.S., Fervenza F.C. Membranoproliferative glomerulonephritis secondary to monoclonalgammopathy. Clin. J. Am. Soc. Nephrol. 2010;5:770-782.
  18. Appel G.B. Membranoproliferative glomerulonephritis - Mechanisms and Treatment. In: Chen N., eds. New Insights into Glomerulonephritis. Contrib. Nephrol. Basel, Karger, 2013. P. 163-174.
  19. Sethi S., Fervenza F.C., Zhang Y., Nasr S.H., Leung N., Vrana J., Cramer C., Nester C.M., Smith R.J. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin. J. Am. Soc. Nephrol. 2011;6:1009-1017.
  20. Sethi S., Gamez J.D., Vrana J.A., Theis J.D., Bergen H.R. 3rd, Zipfel P.F., Dogan A., Smith R.J. Glomeruli of DDD contain components of the alternative and terminal complement pathway. Kidney Int. 2009;75:852-960.
  21. Servais A., Noel L.-H., Fremeaux-Bacchi V. et al. C3 glomerulopathy. In: Chen N (ed). New Insights into Glomerulonephritis. Contrib. Nephrol. Basel, Karger, 2013. P. 163-174.
  22. Barbour T.D., Pickering M.C., Cook H.T. Recent insights into C3 glomerulopathy. Nephrol. Dial. Transplant. 2013;28:1685-1693.
  23. Licht C., Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb. Haemost. 2009;101:271-278.
  24. Smith R.J.H., Alexander J., Barlow P.N., Botto M., Cassavant T.L., Cook H.T., de Córdoba S.R., Hageman G.S., Jokiranta T.S., Kimberling W.J., Lambris J.D., Lanning L.D., Levidiotis V., Licht C., Lutz H.U., Meri S., Pickering M.C., Quigg R.J., Rops A.L., Salant D.J., Sethi S., Thurman J.M., Tully H.F., Tully S.P., van der Vlag J., Walker P.D., Würzner R., Zipfel P.F.; Dense Deposit Disease Focus Group. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 2007;18:2447-2456.
  25. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009;9:729-740.
  26. Sethi S., Fervenza F.C. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin. Thromb. Hemost. 2014;40(4):416-421.
  27. Servais A., Noel L.-H., Roumenina L.T., Le Quintrec M., Ngo S., Dragon-Durey M.A.,Macher M.A.,Zuber J.,KarrasA.,Provot F.,Moulin B.,Grünfeld J.P., Niaudet P., Lesavre P., Frémeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454-464.
  28. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., Vazquez-Martul E., Torreira E., Montes T., Tortajada A., Pinto S., Lopez-Trascasa M., Morgan B.P., Llorca O., Harris C.L., Rodriguez de Córdoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 2010; 120:3702-3712.
  29. Xiao X., Pickering M.C., Smith R.J.H. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin Thromb. Hemost. 2014;40:465-471.
  30. Zhang Y., Meyer N.C., Wang K., Nishimura C., Frees K., Jones M., Katz L.M., Sethi S., Smith R.J. Causes of alternative pathway dysregulation in dense deposit disease. Clin. J. Am. Soc. Nephrol. 2012;7:265-274.
  31. Daga M.R., Van Es L.A. Stabilization of homologous and heterologous cellbound amplification convertases, C3bBb, by C3 nefritic factor. Immunology. 1981;43:33-38.
  32. Appel G.B., Cook H. T.,Hageman G.,JennetteJ. C.,Kashgarian M.,Kirschfink M., Lambris J.D., Lanning L., Lutz H.U., Meri S., Rose N.R., Salant D.J., Sethi S., Smith R.J., Smoyer W., Tully H.F., Tully S.P., Walker P., Welsh M., Würzner R., Zipfel P.F. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J. Am. Soc. Nephrol. 2005;16:1392-1403.
  33. Servais A., Fremeaux-Bacchi V., Lequintrec M., Salomon R., Blouin J., Knebelmann B., Grünfeld J.P., Lesavre P., Noël L.H., Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic yraemic syndrome. J. Med. Genet. 2007;44:193-199.
  34. Chen Q., Muller D., Rudolph B., Hartmann A., Kuwertz-Bröking E., Wu K., Kirschfink M., Skerka C., Zipfel P.F. Combined C3b andfactor B autoantibodies and MPGN type II. N. Engl. J. Med. 2011;365:2340-2342.
  35. Habbig S., Mihatsch M.J., Heinen S., Beck B., Emmel M., Skerka C., Kirschfink M., Hoppe B., Zipfel P.F., Licht C. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int. 2009;75:1230-1234.
  36. Couser W.G., Johnson R.J. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney Int. 2014;86:905-914.
  37. Fakhouri F., Fremeaux-Bacchi V., Noel L.H., Cook H.T., Pickering M.C. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 2010;6:494-499.
  38. Nasr S.H., Valeri A.M., Appel G.B., Sherwinter J., Stokes M.B., Said S.M., Markowitz G.S., DAgati V.D. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 2009;4:22-32.
  39. Walker P.D. Dense deposit disease: new insights. Curr. Opin. Nephrol. Hypertens. 2007;16:204-212.
  40. Walker P.D., Ferrario F., Joh K., Bonsib S.M. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod. Pathol. 2007;20:605-616.
  41. Lu D.F., Moon M., Lanning L.D., McCarthy A.M., Smith R.J., McCarthy A.M., Smith R.J. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr. Nephrol. 2012;27(5):773-781.
  42. Грене Г.-Й., Кисс Е. Нефротический синдром: гистопатологическая дифференциальная диагностика. Часть 3: Мембранозно-пролиферативный гломерулонефрит, IgA нефропатия, диабетическая нефропатия, амилоидоз, пострансплантационная нефропатия. Нефрология. 2008;12(1):84-97.
  43. Scattum L., Martensson U., Sjoholm A.G. Hypocomplementemia caused by C3 nephritic factors (C3 Nef): clinical findings and the coincidence of C3 Nef type IIwith anti-C1q autoantibodies. J. Intern. Med. 1997;242:455-464.
  44. Fervenza F.C., Sethi S., Glassock R.J. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol. Dial. Transplant. 2012;27:4288-4294.
  45. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009;361:1676-1687.
  46. Goldberg R.J., Nakagawa T., Johnson R.J., Thurman J.M. The role of endothelial cell injury in thrombotic microangiopathy. Am. J. Kidney Dis. 2010;56:1168-1174.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>